Literature DB >> 1565904

Monoclonal antibodies and radioimmunoconjugates in the diagnosis and treatment of prostate cancer.

H Abdel-Nabi1, G L Wright, J V Gulfo, D P Petrylak, C E Neal, J E Texter, F P Begun, I Tyson, A Heal, E Mitchell.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1565904

Source DB:  PubMed          Journal:  Semin Urol        ISSN： 0730-9147


× No keyword cloud information.
  5 in total

Review 1.  Capromab pendetide. A review of its use as an imaging agent in prostate cancer.

Authors:  H M Lamb; D Faulds
Journal:  Drugs Aging       Date:  1998-04       Impact factor: 3.923

Review 2.  Comparison of prostate-specific membrane antigen ligands in clinical translation research for diagnosis of prostate cancer.

Authors:  Sagnik Sengupta; Mena Asha Krishnan; Sudeshna Chattopadhyay; Venkatesh Chelvam
Journal:  Cancer Rep (Hoboken)       Date:  2019-04-02

3.  Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase.

Authors:  R E Carter; A R Feldman; J T Coyle
Journal:  Proc Natl Acad Sci U S A       Date:  1996-01-23       Impact factor: 11.205

4.  Prostate-specific membrane antigen: evidence for the existence of a second related human gene.

Authors:  J Leek; N Lench; B Maraj; A Bailey; I M Carr; S Andersen; J Cross; P Whelan; K A MacLennan; D M Meredith
Journal:  Br J Cancer       Date:  1995-09       Impact factor: 7.640

5.  Bone marrow recovery and subsequent chemotherapy following radiolabeled anti-prostate-specific membrane antigen monoclonal antibody j591 in men with metastatic castration-resistant prostate cancer.

Authors:  Scott T Tagawa; Naveed H Akhtar; Anastasia Nikolopoulou; Gurveen Kaur; Brian Robinson; Renee Kahn; Shankar Vallabhajosula; Stanley J Goldsmith; David M Nanus; Neil H Bander
Journal:  Front Oncol       Date:  2013-08-26       Impact factor: 6.244
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.